GI Cryo to Present at Boston Oncology Investor Conference

OWEGO, NY – GI Cryo, Inc a start-up med tech company focused on developing and commercializing novel cryoablation technology platform to treat pancreatic cancer and other gastrointestinal related cancers, announced today that John M. Baust, PhD will deliver a corporate presentation at the Boston Oncology Investor Conference 2019 on Friday, March 15 at 9:35 AM ET. The event will take place at 28 State Street, Boston, MA. Visit www.gicryo.us to learn more about the FrostBite technology platform.

Information about the Boston Oncology Investor Conference 2019 can be found at www.oncologyinvestorconference.com. GI Cryo has partnered with CPSI Biotech to bring the innovative GastroCS and FrostBite EUS Cryocatheter cryoablation platform to commercialization.

Click Here to read the full Press Release: GI Cryo to Present on its Pancreatic Cancer Cryoablation Technology at the Boston Oncology Investor Conference 2019

View other CPSI Biotech news and recent patent announcements

post

CPSI researchers present on the SmartThaw cell thawing system and RevitalICE reagent at ISBiotech Fall Conference

OWEGO, NY — CPSI Biotech president, Dr. John M. Baust (President and Lead Scientist), has been invited to presented at the 2017 ISBioTech 5th Annual Fall Meeting in Virginia Beach, VA (Dec 10-13). CPSI’s podium presentation will detail recent studies focused on improving the thawing process and quality of frozen cell and tissue products using CPSI’s SmartThaw™ device and RevitalICE™ reagent.

Dr. Baust’s presentation will feature studies conducted by CPSI researchers on human hematopoietic and mesenchymal stem cells. Commenting on the research, Dr. Baust stated “our continuing studies demonstrated that sample quality and processing can be improved using SmartThaw™ and RevitalICE™. SmartThaw™ provides improved processing of frozen products while in many cases also improving viability post-thaw. The RevitalICE™ post-thaw recovery reagent is designed to give researchers the ability to salvage samples which have been cryopreserved using dated approaches.”

SmartThaw is targeted for commercial launch in 2018.

Click Here to read the full Press Release: PR20171211_SmartThaw_ISBioTechFallConf

More information on SmartThaw™, RevitalICE™ or any of CPSI’s other technologies is available on CPSI Biotech’s website www.cpsibiotech.com.

More information on the International Society for Bioprocess Technology and the ISBioTech conference series can be found at www.isbiotech.org.

Dr. John M. Baust Presents at ISBiotech 2017

OWEGO, NY — CPSI Biotech’s CEO and Lead Scientist gave a podium presentation Monday morning at the 2017 ISBiotech 7th Annual Spring Meeting in Washington, DC (March 6-8). The presentation titled “New Technologies for Improved Handling of Cryopreserved Samples”, given by Dr. John M. Baust, focused on the recent research and development activities relating to CPSI’s SmartThaw™ dry thawing device and RevitalICE cell culture reagent.

As part of the presentation, Dr. Baust focused on educating and reviewing attendees’ current cryopreservation practices and the challenges associated with many of protocols, as well as discussing new technologies and development efforts in the area of modulating the cellular-molecular response to cryopreservation as a path to improve cell recovery and function. Dr. Baust also presented data recently collected by CPSI scientists related to thawing of samples cryopreserved in 5 ml cryovials using SmartThaw™, a next generation device developed by CPSI Biotech for controlled and rapid dry thawing.

SmartThaw is targeted for commercial launch in 2017.

Click Here to read the full Press Release: CPSI Scientists Present at ISBiotech 2017_PR20170308

View other CPSI Biotech news and recent patent announcements